Limits...
Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis.

Caracò C, Mozzillo N, Marone U, Simeone E, Benedetto L, Di Monta G, Di Cecilia ML, Botti G, Ascierto PA - BMC Cancer (2013)

Bottom Line: A long-lasting response was defined as no cutaneous or in-transit relapse after a minimum of six months.Thirteen patients (44.8% of complete responders) experienced a long-lasting response after one ECT session and were disease-free after a mean duration of follow-up of 27.5 months.The favorable outcome obtained in the present study demonstrates that ECT is a reliable, and effective procedure that provides long-term benefit in terms of curative and palliative treatment for unresectable cutaneous lesions without adversely impacting the quality of life of patients.

View Article: PubMed Central - HTML - PubMed

Affiliation: Unit of Surgery "Melanoma - Soft Tissues - Head & Neck - Skin Cancers", Istituto Nazionale per lo Studio e la cura dei tumori "Fondazione G,Pascale" IRCCS, Naples, Italy. dott.marone@virgilio.it.

ABSTRACT

Background: Treatment of early and multiple cutaneous unresectable recurrences is a major therapeutic problem with around 80% of patients relapsing within 5 years. For lesions refractory to elective treatments, electrochemotherapy (ECT) involving electroporation combined with antineoplastic drug treatment appears to be a new potential option. This study was undertaken to analyze the short- and long-term responses of lesions treated with ECT with intravenous injection of bleomycin in melanoma patients with in-transit disease or distant cutaneous metastases.

Methods: Between June 2007 and September 2012, 60 patients with relapsed and refractory cutaneous melanoma metastases or in-transit disease underwent 100 courses of ECT with intravenous injection of bleomycin. Response to treatment was evaluated three months after ECT. A long-lasting response was defined as no cutaneous or in-transit relapse after a minimum of six months.

Results: Three months after ECT, a complete response was observed in 29 patients (48.4%), a partial response in 23 patients (38.3%) and no change or progressive disease in 8 patients (13.3%). The objective response rate of all treated lesions was 86.6%. Thirteen patients (44.8% of complete responders) experienced a long-lasting response after one ECT session and were disease-free after a mean duration of follow-up of 27.5 months.

Conclusions: The favorable outcome obtained in the present study demonstrates that ECT is a reliable, and effective procedure that provides long-term benefit in terms of curative and palliative treatment for unresectable cutaneous lesions without adversely impacting the quality of life of patients.

Show MeSH

Related in: MedlinePlus

Treatment response.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4219480&req=5

Figure 1: Treatment response.

Mentions: Three months after the ECT session, 23 patients (38.3%) had a PR and 29 had a CR (48.4%). Eight patients (13.3%) had NC or PD. The objective response rate of all treated lesions was 86.6%. A total of 13 patients (21.7% overall, 44.8% of those with a CR) experienced a long-lasting response to ECT after one session and were free of disease after a mean follow-up of 27.5 months (Figure 1).


Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis.

Caracò C, Mozzillo N, Marone U, Simeone E, Benedetto L, Di Monta G, Di Cecilia ML, Botti G, Ascierto PA - BMC Cancer (2013)

Treatment response.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4219480&req=5

Figure 1: Treatment response.
Mentions: Three months after the ECT session, 23 patients (38.3%) had a PR and 29 had a CR (48.4%). Eight patients (13.3%) had NC or PD. The objective response rate of all treated lesions was 86.6%. A total of 13 patients (21.7% overall, 44.8% of those with a CR) experienced a long-lasting response to ECT after one session and were free of disease after a mean follow-up of 27.5 months (Figure 1).

Bottom Line: A long-lasting response was defined as no cutaneous or in-transit relapse after a minimum of six months.Thirteen patients (44.8% of complete responders) experienced a long-lasting response after one ECT session and were disease-free after a mean duration of follow-up of 27.5 months.The favorable outcome obtained in the present study demonstrates that ECT is a reliable, and effective procedure that provides long-term benefit in terms of curative and palliative treatment for unresectable cutaneous lesions without adversely impacting the quality of life of patients.

View Article: PubMed Central - HTML - PubMed

Affiliation: Unit of Surgery "Melanoma - Soft Tissues - Head & Neck - Skin Cancers", Istituto Nazionale per lo Studio e la cura dei tumori "Fondazione G,Pascale" IRCCS, Naples, Italy. dott.marone@virgilio.it.

ABSTRACT

Background: Treatment of early and multiple cutaneous unresectable recurrences is a major therapeutic problem with around 80% of patients relapsing within 5 years. For lesions refractory to elective treatments, electrochemotherapy (ECT) involving electroporation combined with antineoplastic drug treatment appears to be a new potential option. This study was undertaken to analyze the short- and long-term responses of lesions treated with ECT with intravenous injection of bleomycin in melanoma patients with in-transit disease or distant cutaneous metastases.

Methods: Between June 2007 and September 2012, 60 patients with relapsed and refractory cutaneous melanoma metastases or in-transit disease underwent 100 courses of ECT with intravenous injection of bleomycin. Response to treatment was evaluated three months after ECT. A long-lasting response was defined as no cutaneous or in-transit relapse after a minimum of six months.

Results: Three months after ECT, a complete response was observed in 29 patients (48.4%), a partial response in 23 patients (38.3%) and no change or progressive disease in 8 patients (13.3%). The objective response rate of all treated lesions was 86.6%. Thirteen patients (44.8% of complete responders) experienced a long-lasting response after one ECT session and were disease-free after a mean duration of follow-up of 27.5 months.

Conclusions: The favorable outcome obtained in the present study demonstrates that ECT is a reliable, and effective procedure that provides long-term benefit in terms of curative and palliative treatment for unresectable cutaneous lesions without adversely impacting the quality of life of patients.

Show MeSH
Related in: MedlinePlus